How should prostate cancer be managed in 2024? This concise guideline insights paper summarizes the NCCN panel's discussions for the most recent guideline update. It offers clear recommendations for staging, risk assessment, and care of patients across localized, regional, recurrent, and metastatic prostate cancer. This NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence. Key areas covered include initial risk stratification to ensure accurate categorization of patients. The guidelines also outline initial management strategies for very-low-risk disease, offering a tailored approach for these specific cases. This research also address treatment options for nonmetastatic recurrence, providing updated recommendations for managing this challenging clinical scenario. Designed for busy clinicians, this paper offers essential insights into the latest NCCN guidelines, enabling informed decision-making and optimized care for men with prostate cancer. It also summarizes the panel's discussions for the 2024 update to the guidelines.
Published in the Journal of the National Comprehensive Cancer Network, this article directly addresses the journal's focus on providing evidence-based guidelines for cancer care. As an NCCN Guidelines Insights paper, it summarizes the expert panel's discussions and recommendations for managing prostate cancer, a topic central to the journal's mission of improving cancer treatment and outcomes.